AOD-9604 for Sale: How to Evaluate a Vendor Before You Buy
The market for AOD-9604 is crowded and largely unregulated. Here's what the evidence says about the compound and what a credible research-use supplier actually looks like.
When searching for AOD-9604 for sale, prioritize vendors that publish third-party certificates of analysis showing HPLC purity above 98% and mass-spectrometry confirmation of the correct molecular weight. Any vendor making health claims, providing human-use instructions, or selling without a research-use disclaimer is a red flag. AOD-9604 is not FDA approved and exists only as a research chemical in the United States.
What Is AOD-9604 and What Does the Research Actually Show?
AOD-9604 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, specifically amino acids 177 to 191. It was originally developed by Monash University researchers in Australia with the goal of isolating the fat-metabolism effects of growth hormone while avoiding the insulin-resistance and IGF-1-driven side effects associated with the full molecule. The peptide carries the sequence Tyr-hGH177-191 and has a molecular weight of approximately 1817 daltons.
The most frequently cited preclinical work comes from animal studies. A 2000 paper published in the American Journal of Physiology by Heffernan and colleagues examined AOD-9604 in obese mice and reported reductions in body fat alongside effects on fatty acid oxidation. That work was conducted in rodents, which limits how directly the findings translate to humans. Researchers and buyers alike should treat animal data as hypothesis-generating, not as proof of human efficacy.
Human trial data on AOD-9604 is thin. A phase IIb trial conducted by Metabolic Pharmaceuticals in the early 2000s tested the compound in overweight adults, but the program was discontinued before reaching phase III. The FDA never approved AOD-9604 for any indication. In 2014, the FDA issued a notice removing AOD-9604 from the list of bulk drug substances that could be used in compounded preparations, which is a meaningful regulatory signal any buyer should understand before purchasing.
The compound is currently sold in the United States strictly as a research chemical, meaning it is legal to purchase for laboratory and in-vitro research purposes but is not approved for human administration. Any vendor framing it otherwise is misrepresenting its regulatory status.
What Does a Legitimate Research-Compound Vendor Look Like?
The single most important document a peptide vendor can provide is a certificate of analysis, commonly called a COA, issued by an independent third-party laboratory. A COA should report HPLC purity, ideally above 98% for a research-grade peptide, along with mass-spectrometry data confirming the compound's molecular weight matches the theoretical value for AOD-9604. Without both data points, purity claims are unverifiable marketing copy.
Batch transparency matters as much as having a COA at all. A credible vendor ties each product listing to a specific lot number and makes the corresponding COA downloadable directly from the product page. If the COA is undated, lacks a lab name, or cannot be cross-referenced to a real analytical laboratory, treat it as decorative. Some vendors post a single COA for an entire product line rather than per-batch documents; that practice tells you the testing program is superficial.
Look for vendors that test for more than just purity. Residual solvent analysis, sterility testing, and endotoxin testing are relevant for any peptide that will be handled in a research setting. Not every vendor performs all three, but the better ones disclose what they do and do not test for rather than staying silent on the question.
Shipping and storage documentation is another marker of a serious operation. AOD-9604 is a lyophilized powder that degrades with heat and moisture. A vendor that ships without cold packs in summer, provides no storage guidance, or cannot explain the difference between lyophilized and reconstituted stability is cutting corners on product integrity.
Red Flags That Should Stop a Purchase
Health claims are the clearest disqualifier. Any vendor that describes AOD-9604 as something that treats obesity, produces guaranteed fat loss in humans, or carries outcome promises of any kind is making claims that have no FDA-approved basis and that signal the vendor is not operating within research-chemical norms. The same applies to before-and-after photos and testimonials framed as medical outcomes.
Human-use instructions on a product page are a serious red flag. A legitimate research-chemical vendor sells to researchers and labels products accordingly. If a product page includes language about administration schedules, quantities to use, or how to structure a research cycle, the vendor is implicitly marketing for human use, which falls outside the legal framework for an unapproved compound. That kind of content also signals the vendor may not understand, or may not care about, the regulatory environment they operate in.
No COA, or a COA that cannot be verified, is a disqualifier on its own. Some vendors list a COA as a PDF that, on inspection, lacks a laboratory name, an analyst signature, or a date. Others link to a COA from a lab that does not appear to exist as a real analytical chemistry business. If you cannot find the testing laboratory through an independent search, the document should be treated as unreliable.
Pricing that sits far below market norms deserves scrutiny. Peptide synthesis and third-party testing carry real costs. A vendor offering AOD-9604 at a fraction of competitor prices while claiming equivalent purity is almost certainly cutting corners somewhere, whether on raw materials, testing, or storage conditions during fulfillment.
Understanding AOD-9604's Regulatory Position in the United States
The FDA's 2014 decision to exclude AOD-9604 from the 503A bulk compounding list was significant. It meant that compounding pharmacies could no longer prepare the peptide for patient use under that regulatory pathway. Buyers who encounter vendors claiming their AOD-9604 is pharmacy-grade or compounded for human use should treat those claims with skepticism, because the regulatory basis for such a claim no longer exists in the United States.
Research chemicals occupy a specific legal space. They can be purchased, possessed, and used for legitimate laboratory research. They cannot legally be marketed for human consumption, and vendors who blur that line are creating legal exposure for themselves and potentially for buyers. A vendor's research-use disclaimer is not just boilerplate; it is the legal framing that defines what the transaction actually is.
The distinction between a research chemical and a pharmaceutical also matters for quality expectations. Pharmaceutical manufacturing follows current Good Manufacturing Practice, known as cGMP, standards enforced by the FDA. Research-chemical vendors are not held to cGMP standards, which is precisely why independent third-party COAs become the buyer's primary quality signal. There is no regulatory body routinely auditing these vendors on the buyer's behalf.
Buyers should also be aware that the peptide market has attracted counterfeit products. Independent community testing projects, including work published through platforms like Janoshik Analytical, have found that a meaningful share of peptides purchased from unvetted vendors contain the wrong compound, degraded material, or significantly lower purity than advertised. That reality makes COA verification a practical necessity, not an optional step.
Sourcing Criteria: What to Check Before Any Purchase
A vendor worth considering will meet several baseline criteria. The product listing will carry a clear research-use-only statement. A per-batch COA from a named, verifiable third-party laboratory will be accessible without requiring a customer account or a direct request. The COA will include both HPLC purity data and mass-spectrometry confirmation, and it will be dated within a reasonable window of the current inventory.
Beyond documentation, look at how the vendor communicates. A company that answers questions about testing methodology, storage conditions, and return policies is demonstrating operational competence. A company that deflects those questions, responds with vague assurances, or points back to marketing copy is signaling that the documentation may be the weakest part of their operation.
Refund and replacement policies matter for research budgets. Peptides can arrive degraded if cold-chain handling fails. A vendor with no stated policy on damaged or mislabeled shipments offers no recourse when something goes wrong. Check whether the policy covers both shipping damage and purity disputes, and whether it requires the buyer to return the product or simply provide photographic evidence.
The final check is consistency over time. Vendors that maintain batch records, update COAs with each new lot, and keep their testing documentation current are running a real quality program. Vendors whose COA dates never change, regardless of when you check, are likely posting static documents that do not reflect actual ongoing testing. That pattern is worth noting before committing to a purchase.
Vetted vendors for research use
Our index screens vendor documentation against the checks in this review. We never accept payment for rank placement.
Frequently asked questions
Is AOD-9604 legal to buy in the United States?
AOD-9604 can be purchased legally in the United States as a research chemical for laboratory use. It is not approved by the FDA for human use, and the agency removed it from the list of bulk substances permitted in compounded preparations in 2014. Vendors are required to label it for research purposes only.
What should a COA for AOD-9604 actually contain?
A credible COA should include the product name and lot number, the name and contact information of the issuing laboratory, a date of analysis, HPLC chromatography data showing purity as a percentage, and mass-spectrometry data confirming the molecular weight matches the theoretical value for AOD-9604 at approximately 1817 daltons. A document missing any of those elements cannot be used to verify product quality.
How does the 2014 FDA compounding decision affect buyers today?
The FDA's 2014 action placed AOD-9604 on the list of bulk drug substances that may not be used in compounded drug preparations under section 503A of the Federal Food, Drug, and Cosmetic Act. In practical terms, this means no compounding pharmacy can legally prepare AOD-9604 for patient administration in the United States. Any vendor claiming their product is pharmacy-compounded or approved for human use is making a claim that conflicts with current federal regulatory status.
Sources
Sources are listed most recent first. Cited studies are peer-reviewed unless noted.
- Heffernan et al., 2000, American Journal of Physiology Preclinical rodent study on AOD-9604 fat metabolism
- Heffernan et al., 2001, Journal of Endocrinology Follow-up animal data on AOD-9604 lipolytic activity
Educational and informational content only. This is not medical advice, diagnosis, or treatment. The compounds discussed are research compounds not approved by the FDA or any equivalent authority for human use outside prescribed contexts. Always consult a licensed clinician before any health decision.
